# *Efnb2* Cas9-CKO Strategy

**Designer:** Daohua Xu
**Reviewer:** Huimin Su
**Design Date:** 2019-11-25

# Project Overview

| | |
|---|---|
| **Project Name** | ***Efnb2*** |
| **Project type** | **Cas9-CKO** |
| **Strain background** | **C57BL/6JGpt** |

# Conditional Knockout strategy

This model will use CRISPR/Cas9 technology to edit the *Efnb2* gene. The schematic diagram is as follows:



# Technical routes

- The *Efnb2* gene has 3 transcripts. According to the structure of *Efnb2* gene, exon2 of *Efnb2-201* (ENSMUST00000001319.14) transcript is recommended as the knockout region.The region contains 284bp coding sequence. Knock out the region will result in disruption of protein function.

- In this project we use CRISPR/Cas9 technology to modify *Efnb2* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6JGpt mice.Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.

- The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.

# Notice

- According to the existing MGI data,Homozygotes for targeted null mutations exhibit defects in angiogenesis of both arteries and veins and die by embryonic day 11.5.

- The *Efnb2* gene is located on the Chr8. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.

- This Strategy is designed based on genetic information in existing databases.Due to the complexity of biological processes, all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.

# Gene information （NCBI）

集萃药康 GemPharmatech

## Efnb2 ephrin B2 [Mus musculus (house mouse)]

Gene ID: 13642, updated on 5-Mar-2019

### Summary

| | |
|---|---|
| **Official Symbol** | Efnb2 provided by MGI |
| **Official Full Name** | ephrin B2 provided by MGI |
| **Primary source** | MGI:MGI:105097 |
| **See related** | Ensembl:ENSMUSG00000001300 |
| **Gene type** | protein coding |
| **RefSeq status** | VALIDATED |
| **Organism** | Mus musculus |
| **Lineage** | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus |
| **Also known as** | ELF-2, Epl5, Eplg5, Htk-L, LERK-5, Lerk5, NLERK-1 |
| **Expression** | Broad expression in lung adult (RPKM 20.3), colon adult (RPKM 11.2) and 23 other tissues See more |
| **Orthologs** | human all |

# Transcript information（Ensembl）

The gene has 3 transcripts,all transcripts are shown below:

| Name | Transcript ID | bp | Protein | Biotype | CCDS | UniProt | Flags |
|---|---|---|---|---|---|---|---|
| Efnb2-201 | ENSMUST00000001319.14 | 4793 | 336aa | Protein coding | CCDS22090 | P52800 Q4FJM3 | TSL:1 GENCODE basic APPRIS P1 |
| Efnb2-202 | ENSMUST00000152698.1 | 652 | 218aa | Protein coding | - | F6RSU6 | 5' and 3' truncations in transcript evidence prevent annotation of the start and the end of the CDS. CDS 5' and 3' incomplete TSL:3 |
| Efnb2-203 | ENSMUST00000209169.1 | 2818 | No protein | Retained intron | - | - | TSL:NA |

The strategy is based on the design of *Efnb2-201* transcript,The transcription is shown below



# Genomic location distribution



# Protein domain



# Mouse phenotype description(MGI )


*Phenotypes affected by the gene are marked in blue.Data quoted from MGI database(http://www.informatics.jax.org/).*

According to the existing MGI data,Homozygotes for targeted null mutations exhibit defects in angiogenesis of both arteries and veins and die by embryonic day 11.5.

集萃药康
GemPharmatech

If you have any questions, you are welcome to inquire.

Tel: 400-9660890

集萃药康生物科技
GemPharmatech Co.,Ltd